Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Clinical trial NCT06398457 · RECRUITING

Trial details

NCT number: NCT06398457
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Hematologic Malignancy Bone Marrow Transplant Rejection Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)Acute Lymphoblastic Leukemia (ALL), Adult Multiple Myeloma Aplastic Anemia Lymphoma Non Hodgkin Lymphoma Hodgkin Lymphoma Chronic Myeloid Leukemia Myelofibrosis

Start date: 2024-09-19
Primary completion: 2026-09-01
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.